Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
  • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
  • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
  • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D309/10—Oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
  • C07H7/04—Carbocyclic radicals

Definitions

• the invention relates to a crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4- ⁇ B-D- glucopy ranos- 1 -yl)- enzene , to methods for the preparation thereof, as well as to the use thereof for preparing medicaments.
• the compounds described therein have a valuable inhibitory effect on the sodium-dependent glucose cotransporter SGLT, particularly SGLT2.
• the method of manufacture of the compound A as described therein does not yield a crystalline form.
• a certain pharmaceutical activity is of course the basic prerequisite to be fulfilled by a pharmaceutically active agent before same is approved as a medicament on the market.
• a pharmaceutically active agent has to comply with. These requirements are based on various parameters which are connected with the nature of the active substance itself. Without being restrictive, examples of these parameters are the stability of the active agent under various environmental conditions, its stability during production of the pharmaceutical formulation and the stability of the active agent in the final medicament compositions.
• the pharmaceutically active substance used for preparing the pharmaceutical compositions should be as pure as possible and its stability in long-term storage must be guaranteed under various environmental conditions. This is essential to prevent the use of pharmaceutical compositions which contain, in addition to the actual active substance, breakdown products thereof, for example.
• compositions with a tendency to absorb moisture have to be protected from moisture during storage, e.g. by the addition of suitable drying agents or by storing the drug in an environment where it is protected from moisture.
• a pharmaceutically active substance should be at best slightly hygroscopic.
• the aim of the invention is thus to provide a new, stable crystalline form of the compound A which meets important requirements imposed on pharmaceutically active substances as those mentioned above.
• a further aspect of the present invention relates to the crystalline complex for use as a medicament.
• the present invention relates to a use of one or more crystalline complexes as defined hereinbefore or hereinafter for preparing a pharmaceutical composition for inhibiting the sodium-dependent glucose cotransporter SGLT2.
• the present invention relates to a method for making one or more crystalline complexes as defined hereinbefore and hereinafter, said method comprising the following steps:
• the Figure 1 shows an X-ray powder diffractogram of the crystalline complex between the compound A and L-proline.
• the present invention relates to a crystalline complex between the compound A and one or more natural amino acids.
• crystalline complexes according to this invention are preferred which are formed between the compound A and one natural amino acid, most preferably between the compound A and the (L) enantiomer of a natural amino acid.
• the crystalline complex is characterized in that the natural amino acid is proline, in particular (L)-proline.
• the molar ratio of the compound A and the natural amino acid is in the range from about 2 : 1 to about 1 : 3; more preferably from about 1.5 : 1 to about 1 : 1.5, even more preferably from about 1.2 : 1 to about 1 : 1.2, most preferably about 1 : 1 .
• a preferred crystalline complex according to this invention is a complex (1 : 1) between the compound A and proline; in particular of the compound A and L-proline.
• the molar ratio of the crystalline complex and water is in the range from about 1 : 0 to 1 : 3; more preferably from about 1 : 0 to 1 : 2, even more preferably from about 1 ; 0.5 to 1 : .5, most preferably about 1 : 0.8 to 1 : 1.2, in particular about 1 : 1 ,
• the crystalline complex of the compound A with proline in particular of the compound A with L-proline and water, may be identified and distinguished from other crystalline forms by means of their characteristic X-ray powder diffraction (XRPD) patterns.
• Said crystalline complex is preferably characterised by an X-ray powder diffraction pattern that comprises peaks at 20.28, 21.14 and 21.64 degrees 20 ( ⁇ 0.1 degrees 2 ⁇ ), wherein said X-ray powder diffraction pattern is made using CuK a j radiation.
• said X-ray powder diffraction pattern comprises peaks at 4.99, 20.28, 21.14, 21.64 and 23.23 degrees 2 ⁇ ( ⁇ 0.1 degrees 2 ⁇ ), wherein said X-ray powder diffraction pattern is made using CuK a j radiation.
• said X-ray powder diffraction pattern comprises peaks at 4.99, 17.61 , 17.77, 20.28, 21.14, 21.64, 23.23 and 27.66 degrees 2 ⁇ ( ⁇ 0.1 degrees 2 ⁇ ), wherein said X- ray powder diffraction pattern is made using CuK a j radiation.
• said X-ray powder diffraction pattern comprises peaks at 4.99, 15.12, 17.61 , 17.77, 18.17, 20.28, 21.14, 21.64, 23.23 and 27.66 degrees 2 ⁇ ( ⁇ 0.1 degrees 2 ⁇ ), wherein said X-ray powder diffraction pattern is made using CuK a j radiation.
• the crystalline complex of the compound A and L-proline is characterised by an X-ray powder diffraction pattern, made using CuK a j radiation, which comprises peaks at degrees 2 ⁇ ( ⁇ 0.1 degrees 2 ⁇ ) as contained in Table 1.
• Table 1 X-ray powder diffraction pattern of the crystalline complex of the compound A and L-proline (only peaks up to 30° in 2 ⁇ are listed): ⁇ d-vafue intensity l/l 0
• said crystalline complex is characterised by an X-ray powder diffraction pattern, made using CuK a j radiation, which comprises peaks at degrees 2 ⁇ ( ⁇ 0.1 degrees 2 ⁇ ) as shown in Figure 1.
• the above described 2 ⁇ values should be considered accurate to ⁇ 0.1 degrees 2 ⁇ , in particular ⁇ 0.05 degrees 2 ⁇ . That is to say, when assessing whether a given sample of crystals of the compound A is the crystalline form in accordance with the invention, a 2 ⁇ value which is experimentally observed for the sample should be considered identical with a characteristic value described above if it falls within ⁇ 0.1 degrees 2 ⁇ of the characteristic value, in particular if it falls within ⁇ 0.05 degrees 2 ⁇ of the characteristic value.
• a preferred volume ratio of water : the alkanol is in the range from about 99 : 1 to 1 : 99; more preferably from about 50 : 1 to 1 ; 80; even more preferably from about 10 : 1 to 1 : 60.
• the starting material of the compound A and/or of the one or more natural amino acids and/or of the solvent and mixtures of solvents contain an amount of H 2 0 which is at least the quantity required to form a hydrate of the compound A; in particular at least 1 mol, preferably at least 1.5 mol of water per mol of compound A. Even more preferably the amount of water is at least 2 mol of water per mol of compound A.
• step (a) if the starting material of the compound A or of the natural amino acid in step (a) does contain sufficient water as specified above, a water content of the solvent(s) is not mandatory.
• one or more antisolvents may be added, preferably during step (a) or at the beginning of step (b).
• Water is an example of a suitable antisolvent.
• the amount of antisolvent is preferably chosen to obtain a supersaturated or saturated solution with respect to the crystalline complex.
• step (b) the solution is stored for a time sufficient to obtain a precipitate, i.e. the crystalline complex.
• the temperature of the solution in step (b) is about the same as or lower than in step (a).
• the temperature of the solution is preferably lowered, preferably to a temperature in the range of 20°C to 0°C or even lower.
• the step (b) can be carried out with or without stirring.
• the size, shape and quality of the obtained crystalls can be controlled.
• the crystallization may be induced by methods as known in the art, for example by mechanical means such as scratching or rubbing the contact surface of the reaction vessel for example with a glass rod.
• the (nearly) saturated or supersaturated solution may be inoculated with seed crystalls.
• the solvent(s) can be removed from the precipitate by known methods as for example filtration, suction filtration, decantation or centrifugation.
• the compound A may be synthesized by methods as specifically and/or generally described or cited in the international application WO 2007/ 128749. Furthermore the biological properties of the compound A may be investigated as it is described in the international application WO 2007/ 128749 which in their entirety are incorporated herein by reference.
• the crystalline complex in accordance with the invention is preferably employed as drug active substance in substantially pure form, that is to say, essentially free of other crystalline forms of the compound A. Nevertheless, the invention also embraces the crystalline complex in admixture with another crystalline form or forms. Should the drug active substance be a mixture of crystalline forms, it is preferred that the substance comprises at least 50%-weight, even more preferably at least 90%-weight, most preferably at least 95%-weight of the crystalline complex as described herein.
• the crystalline complex according to the invention is suitable for the use in the treatment and/or preventive treatment of conditions or diseases which may be affected by the inhibition of the SGLT activity, particularly the SGLT- 2 activity.
• the crystalline complex according to the invention is also suitable for the preparation of pharmaceutical compositions for the treatment and/or preventive treatment of conditions or diseases which may be affected by the inhibition of the SGLT activity, particularly the SGLT- 2 activity. Therefore, the crystalline complex according to the invention is suitable for the use in the treatment of type 2 diabetes mellitus in humans.
• H atoms of hydroxyl groups are not explicitly shown in every case in structural formulae.
• the following example of synthesis serves to illustrate a method of preparing the compound A and its crystalline complex with L-proline as a natural amino acid. It is to be regarded only as a possible method described by way of example, without restricting the invention to its contents.
• the terms "room temperature” and “ambient temperature” are used interchangeably and denote temperatures of about 20°C.
• the following abbreviations are used:
• Phenol (13 g) dissolved in 4 KOH solution (60 mL) is added to 4-bromo-3-chloromethyl- 1 - iodo- enzene (41.0 g) dissolved in acetone (50 mL).
• Nal (0.5 g) is added and the resulting mixture is stirred at 50 °C overnight.
• water is added and the resulting mixture is extracted with ethyl acetate.
• the combined extracts are dried (Na 2 SO Register) and the solvent is evaporated under reduced pressure.
• the residue is purified by chromatography on silica gel (cyclohexane/ethyl acetate 19:1).
• the resulting solution is warmed to -5 °C in the cooling bath and stirred for another 30 min at this temperature.
• Aqueous NH 4 CI solution is added and the resultant mixture is extracted with ethyl acetate.
• the combined organic extracts are dried over sodium sulfate and the solvent is removed under reduced pressure.
• the residue is dissolved in methanol (80 mL) and treated with methanesulfonic acid (0.6 mL) to produce the more stable anomer solely.
• the solution is neutralized with solid NaHC0 3 and the methanol is removed under reduced pressure.
• the remainder is diluted with aqueous NaHC0 3 solution and the resulting mixture is extracted with ethyl acetate.
• the combined extracts are dried over sodium sulfate and the solvent is evaporated to yield the crude product that is submitted to reduction without further- purification.
• the resultant solution is warmed to 0 °C over a period of 1.5 h and then treated with aqueous sodium hydrogen carbonate solution.
• the resulting mixture is stirred for 0.5 h, the organic solvent is removed and the residue is extracted with ethyl acetate. The combined organic layers are dried over sodium sulfate and the solvent is removed.
• the residue is taken up in dichloromethane (50 mL) and pyridine (9.4 mL), acetic anhydride (9.3 mL) and 4-dimethylaminopyridine (0.5 g) are added in succession to the solution.
• the solution is stirred for 1.5 h at ambient temperature and then diluted with dichloromethane.
• the compound described above is synthesized starting from 1-bromo-4- (2,3,4,6-tetra-0-acetyl-D-glucopyranos-1-yl)-2-(phenoxymethyl)-benzene using copper(l) cyanide (2 equivalents) in NMP at 210 °C.
• aqueous phase is extracted with ethyl acetate and the combined organic phases are dried (sodium sulfate). The solvent is evaporated and the residue is washed with a mixture of ether and cyclohexane to give the product as a colorless solid.
• Residual solvent is removed by storing the crystals at slightly elevated temperature (30 to 50 °C) under vacuum for about 4 h to yield 1.27 g of the crystalline 1 : 1 complex of L-proline and 1 -cyano-2-(4-cyclopropyl-benzyl)-4-(S-D-glucopyranos-1-yl)-benzene.
• the X-ray powder diffraction patterns coincide.
• the melting points are determined via DSC and evaluated as onset-temperature. Examples of melting points are approximately 89°C, 90°C, 92°C, 101 °C and 110°C.
• the X-ray powder diffraction pattern as contained in Table 1 and as depicted in Fig. 1 and the DSC and TG diagram in Fig. 2 correspond to a batch with a melting point of approximately 90°C.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Diabetes (AREA)
• Molecular Biology (AREA)
• Genetics & Genomics (AREA)
• Biotechnology (AREA)
• Biochemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Obesity (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• General Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Hematology (AREA)
• Endocrinology (AREA)
• Emergency Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Saccharide Compounds (AREA)
• Pyrane Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Medicinal Preparation (AREA)

Priority Applications (16)

Applications Claiming Priority (2)

Publications (1)

Family

ID=48874313

Family Applications (1)

Country Status (23)

Cited By (20)

Families Citing this family (3)

Citations (2)

Family Cites Families (17)

• 2013
  • 2013-07-23 US US13/948,751 patent/US9145434B2/en active Active
  • 2013-07-25 HU HUE18155079A patent/HUE061450T2/hu unknown
  • 2013-07-25 PL PL13740309T patent/PL2877460T3/pl unknown
  • 2013-07-25 ES ES13740309.3T patent/ES2694675T3/es active Active
  • 2013-07-25 JP JP2015523552A patent/JP6538556B2/ja active Active
  • 2013-07-25 PT PT181550799T patent/PT3351539T/pt unknown
  • 2013-07-25 DK DK18155079.9T patent/DK3351539T3/da active
  • 2013-07-25 CN CN201380037186.1A patent/CN104470908A/zh active Pending
  • 2013-07-25 EP EP22202153.7A patent/EP4166548A1/en active Pending
  • 2013-07-25 EA EA201600506A patent/EA201600506A1/ru unknown
  • 2013-07-25 EP EP18155079.9A patent/EP3351539B1/en active Active
  • 2013-07-25 CN CN201810468431.9A patent/CN108774200A/zh active Pending
  • 2013-07-25 CA CA2878698A patent/CA2878698C/en active Active
  • 2013-07-25 BR BR112015001327-9A patent/BR112015001327B1/pt active IP Right Grant
  • 2013-07-25 HR HRP20230081TT patent/HRP20230081T1/hr unknown
  • 2013-07-25 PL PL18155079.9T patent/PL3351539T3/pl unknown
  • 2013-07-25 MX MX2015000962A patent/MX357906B/es active IP Right Grant
  • 2013-07-25 AR ARP130102660A patent/AR091908A1/es unknown
  • 2013-07-25 RS RS20230025A patent/RS63881B1/sr unknown
  • 2013-07-25 AU AU2013294947A patent/AU2013294947B2/en active Active
  • 2013-07-25 SG SG11201500574QA patent/SG11201500574QA/en unknown
  • 2013-07-25 HR HRP20181972TT patent/HRP20181972T1/hr unknown
  • 2013-07-25 SI SI201331237T patent/SI2877460T1/sl unknown
  • 2013-07-25 LT LTEP18155079.9T patent/LT3351539T/lt unknown
  • 2013-07-25 WO PCT/EP2013/065736 patent/WO2014016381A1/en not_active Ceased
  • 2013-07-25 TW TW102126724A patent/TW201418275A/zh unknown
  • 2013-07-25 PT PT13740309T patent/PT2877460T/pt unknown
  • 2013-07-25 SI SI201332031T patent/SI3351539T1/sl unknown
  • 2013-07-25 EP EP13740309.3A patent/EP2877460B1/en active Active
  • 2013-07-25 EA EA201500038A patent/EA025438B1/ru not_active IP Right Cessation
  • 2013-07-25 ES ES18155079T patent/ES2937665T3/es active Active
  • 2013-07-25 DK DK13740309.3T patent/DK2877460T3/en active
• 2018
  • 2018-05-08 JP JP2018089968A patent/JP2018135384A/ja active Pending
• 2022
  • 2022-07-25 FI FIEP18155079.9T patent/FI3351539T3/fi active

Patent Citations (2)

Also Published As

Similar Documents

Legal Events